Ligand Pharmaceuticals (NASDAQ:LGND) is set to announce its earnings results before the market opens on Monday, August 3rd. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Ligand Pharmaceuticals has set its FY 2020
After-Hours guidance at 3.65-3.65 EPS and its FY20 guidance at approx $3.65 EPS.Parties interested in participating in the company’s conference call can do so using this link.
Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.23. The business had revenue of $33.16 million for the quarter, compared to the consensus estimate of $26.70 million. Ligand Pharmaceuticals had a positive return on equity of 3.68% and a negative net margin of 55.63%. The business’s revenue was down 23.7% on a year-over-year basis. During the same quarter last year, the business posted $1.16 EPS. On average, analysts expect Ligand Pharmaceuticals to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of NASDAQ LGND opened at $117.18 on Friday. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -34.06, a price-to-earnings-growth ratio of 3.21 and a beta of 1.64. Ligand Pharmaceuticals has a 12-month low of $57.24 and a 12-month high of $127.80. The company has a current ratio of 40.65, a quick ratio of 40.29 and a debt-to-equity ratio of 0.69. The stock’s 50 day simple moving average is $115.59 and its 200 day simple moving average is $99.38.
In related news, SVP Charles S. Berkman sold 11,146 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $118.59, for a total value of $1,321,804.14. Following the sale, the senior vice president now directly owns 40,877 shares in the company, valued at approximately $4,847,603.43. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 8.40% of the stock is owned by company insiders.
LGND has been the topic of several recent research reports. Zacks Investment Research downgraded Ligand Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $131.00 price target on the stock. in a report on Tuesday, July 7th. BidaskClub raised Ligand Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. Benchmark raised their target price on Ligand Pharmaceuticals from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. ValuEngine cut Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, HC Wainwright restated a “buy” rating and issued a $229.00 target price on shares of Ligand Pharmaceuticals in a research report on Monday, June 15th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Ligand Pharmaceuticals currently has an average rating of “Buy” and an average price target of $165.40.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Further Reading: Understanding the two types of arbitrage
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.